Sutro Biopharma (NASDAQ:STRO) Upgraded by Truist Financial to “Strong-Buy” Rating

Sutro Biopharma (NASDAQ:STRO) was upgraded by stock analysts at Truist Financial to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Several other brokerages have also recently issued reports on STRO. Citigroup upgraded Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Wells Fargo & Company raised shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $8.00 to $27.00 in a report on Tuesday. Wedbush restated a “neutral” rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. HC Wainwright raised shares of Sutro Biopharma from a “neutral” rating to a “buy” rating and lifted their price target for the company from $10.00 to $28.00 in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Sutro Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $37.29.

Sutro Biopharma Trading Down 0.3%

Shares of STRO opened at $23.50 on Wednesday. The firm has a market cap of $199.99 million, a price-to-earnings ratio of -0.90 and a beta of 1.47. The stock has a 50 day moving average of $18.61 and a 200-day moving average of $12.76. Sutro Biopharma has a 52 week low of $5.23 and a 52 week high of $26.54.

Institutional Investors Weigh In On Sutro Biopharma

Hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. boosted its holdings in shares of Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after acquiring an additional 53,390 shares during the period. AQR Capital Management LLC lifted its position in Sutro Biopharma by 1,052.8% in the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock valued at $859,000 after purchasing an additional 1,206,330 shares during the last quarter. Strs Ohio bought a new stake in Sutro Biopharma in the 1st quarter valued at about $99,000. Marshall Wace LLP acquired a new position in Sutro Biopharma during the 2nd quarter valued at about $166,000. Finally, Cerity Partners LLC grew its position in Sutro Biopharma by 169.9% in the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock worth $75,000 after purchasing an additional 66,372 shares during the last quarter. 96.99% of the stock is currently owned by institutional investors.

Key Stories Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55 (from $51) and kept a Buy rating — a materially higher target that suggests strong upside vs. the current share price and supports bullish investor expectations. Deutsche Bank raises PT to $55
• Positive Sentiment: Wells Fargo upgraded STRO from Equal Weight to Overweight and raised its price target to $27 (from $8), signaling improving institutional sentiment and providing a nearer-term upside anchor for the stock. Wells Fargo upgrade
• Positive Sentiment: HC Wainwright upgraded STRO from Neutral to Buy and raised its target to $28 (from $10). The firm also published FY2030 EPS projections (large negative EPS expected), but maintained a Buy stance and higher target — a supportive signal from a biotech-focused shop. HC Wainwright upgrade HC Wainwright EPS note
• Neutral Sentiment: Short-interest reports for March show anomalous values (reported as 0 shares with NaN changes and 0.0 days-to-cover across different volume baselines). The data appears unreliable or reflects a reporting/clearing event, so its immediate impact on price is unclear. (Multiple internal short-interest notices consolidated)

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.